GlassScriptPhysician profile
Alka M Arora
NPI 1265621817
$2,923.82
in general payments reported to CMS, 2019-2025
22 companies · $585 in 2025
The $585 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.63 · 2020: $134 · 2021: $292 · 2022: $113 · 2023: $878 · 2024: $827 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020 · Honoraria: $200 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.64 |
| Honoraria | $200.00 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $506.97 | 2019-2025 | Datroway |
| Astrazeneca Pharmaceuticals LP | $494.22 | 2021-2024 | Andexxa, Enhertu |
| Beigene USA, INC. | $345.69 | 2023-2024 | Brukinsa |
| Lilly USA, LLC | $191.10 | 2023-2025 | Verzenio |
| Genentech USA, INC. | $189.35 | 2019-2025 | Tecentriq, Phesgo, Perjeta |
| Pfizer INC. | $126.50 | 2025 | |
| Puma Biotechnology, INC. | $119.99 | 2025 | |
| Pharmacosmos Therapeutics INC. | $113.85 | 2023 | Monoferric |
| Blueprint Medicines Corporation | $112.89 | 2024 | Ayvakit |
| Janssen Pharmaceuticals, INC | $104.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.64 | 2024 | Fruzaqla |
| Boston Scientific Corporation | $94.56 | 2023-2025 | Embold Fibered, Ranger |
| Sobi, INC | $88.24 | 2023 | |
| Endomagnetics LTD | $70.48 | 2023 | Magseed, Magtrace |
| Novartis Pharmaceuticals Corporation | $62.25 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $59.99 | 2019 | |
| Janssen Scientific Affairs, LLC | $43.13 | 2025 | Tecvayli, Talvey, Darzalex |
| Inari Medical, INC. | $26.41 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Celgene Corporation | $25.72 | 2023 | Reblozyl |
| Abbvie INC. | $21.93 | 2024 | |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.